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Results demonstrate the importance of sensitivity analyses and thoughtful 
consideration of the metric and benchmark selection.  
 
PRM45  
HEALTH RESOURCE UTILIZATION OF LUPUS NEPHRITIS PATIENTS – A 
COMPARISON OF RESULT ACROSS CASE IDENTIFICATION ALGORITHMS  
Yeh WS, Clark DW, McCarty KM 
Biogen Idec, Weston, MA, USA  
OBJECTIVES: Lupus nephritis (LN) is a severe complication of systemic lupus 
erythematosus (SLE). While LN has no designated ICD-9 code, various 
approaches have been used to identify patients in administrative data. The 
objective was to compare health resource utilization of LN patients using 
different algorithms in a single data source. METHODS: This study used the 
Impact Database, a commercial insurance claims database. SLE patients were 
identified using ICD-9 code 710.0 from ≥2 outpatient or 1 inpatient claims from 
01/2004 to 06/2011. SLE patients with LN were further identified under four 
different algorithms: (A) ≥1 renal diagnosis, (B) ≥2 renal diagnoses, (C) ≥3 renal 
diagnoses, and (D) ≥3 renal diagnoses plus ≥3 nephrologist visits. Health resource 
utilization and expenditure of outpatient/emergency department (ED) visits, 
hospitalizations, and prescriptions were examined for 12 months post index date 
of first renal diagnosis. RESULTS: A total of 93,957 patients were diagnosed with 
SLE. Among them, 24,357, 11,054, 8,895, and 6,307 cases had LN using algorithms 
A-D. LN cases identified by algorithms A-D had similar mean age (48.3, 46.7, 46.3, 
and 45.7 years) and gender distribution (85.2, 83.1, 82.7, and 81.8% females). LN 
patients from different algorithms also had similar annual frequency of 
outpatient visit (35.9, 41.0, 41.1, and 42.1), ED visit (1.4, 1.4, 1.4, and 1.5), 
hospitalization (0.8, 0.9, 0.9, and 0.9), and prescription (6.8, 7.3, 7.2, and 7.4). The 
annual medical expenditures were $33,176, $36,974, $36,241, and $38,883 for 
algorithms A, B, C, and D, respectively. CONCLUSIONS: Our results support that 
when studying health resource utilization, the results do not differ significantly 
based on the number of renal diagnoses codes. There is a difference in outcomes 
when requiring number of patients plus specialty subtype; however, in the case 
where specialty information is either unavailable or unreliable, using algorithms 
A-C proved equally reliable in an administrative claims database.  
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ANALYSIS OF HEALTH CARE COSTS CONTAINING A LARGE PROPORTION OF  
$0 DATA USING TRADITIONAL AND ZERO-INFLATED GAMMA REGRESSION 
MODELS  
Kern DM, Wasser T 
HealthCore, Inc., Wilmington, DE, USA  
OBJECTIVES: Compare traditional and zero-inflated gamma regression models 
for the analysis of health care costs in an administrative claims database. 
Gamma regression models are widely used for the analysis of health care cost 
data and are appropriate for analyzing mean costs within patients incurring >$0. 
However, little research is available for the appropriateness of gamma regression 
on data with a high proportion of $0 costs. METHODS: This study used the 
HealthCore Integrated Research Environment to analyze hospitalization costs 
within 3,049 bipolar patients initiating antipsychotic medications (Drug X=2,398 
patients; Drug Y=651 patients). Results of a traditional gamma model and a zero-
inflated gamma model were compared. The zero-inflated model used SAS 
procedure NLMIXED to perform logistic regression modelling the probability of 
having a hospitalization, gamma regression modelling mean costs within 
patients having a hospitalization, and combining the two models to analyze 
differences in overall mean cost. RESULTS: There were 18.3% Drug X patients 
with an inpatient hospitalization, compared with 12.1% of Drug Y. Mean costs 
were higher for Drug X within only patients having an event ($17,721 vs. $11,425) 
and including patients with no event ($3,237 vs. $1,387). Gamma regression 
found the difference in the overall population to be significant (mean-
diff=$1,850, CI=[$1,463;$2,152], p<0.0001). The zero-inflated gamma regression 
model showed similar results (mean-diff=$1,850, CI=[$1,237;$2,464], p<0.0001). 
Consistent results between the models were also seen when adjusting for 
patient demographics, comorbidities, and prior medications: traditional gamma 
model (mean-diff=$2,173, CI=[$716;$1,297], p<0.0001), zero-inflated gamma 
model (mean-diff=$2,448, CI=[$597;$1,670], p<0.0001). CONCLUSIONS: When 
analyzing health care cost data containing >80% $0 costs, little difference was 
seen between traditional gamma regression and zero-inflated gamma regression 
models. The zero-inflated model uses complex coding, and requires advanced 
knowledge of statistical methods and SAS programming. Within data containing 
a large proportion of $0 costs, traditional gamma regression is appropriate for 
analyzing differences in mean costs.  
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DIAGNOSTICS FOR CHECKING THE GAMMA DISTRIBUTION ASSUMPTION IN 
GENERALIZED LINEAR MODELS USED FOR MODELING HEALTH CARE COSTS  
Juneau P1, Pan KY2, Curkendall SM3 
1Truven Health Analytics, Bethesda, MD, USA, 2Truven Health Analytics, Cambridge, MA, USA, 
3Truven Health Analytics, Washington, DC, USA  
OBJECTIVES: 1) To study the relative performance of various graphical and 
analytical diagnostics used to assess the assumption of an underlying gamma 
distribution for a commonly used model in the examination of health care 
expenditures (GLMAGALL – a generalized linear model assuming a gamma 
distribution with a log link relating the mean costs to a corresponding set of 
predictors), and 2) To investigate each diagnostic’s ability to discriminate 
between various assumed distributions (e.g., gamma versus log-normal) that 
may be potentially used in health care cost analysis. METHODS: Data sets will be 
created via Monte Carlo simulation of gamma (varying the shape and scale 
parameters) and other distributions, as well as, by altering the values for a small 
set of predictors. The results of the diagnostic study will be illustrated in a 
graphical and/or tabular format. RESULTS: Graphical diagnostics afford the 
analyst the ability to see subtle or dramatic departures from the model’s 
distributional assumptions that might not be as obvious by using an analytical 
model that provides a single summary statistic. CONCLUSIONS: The 
performance of a diagnostic procedure to assess the presence of a gamma 
distribution in a cost model or its ability to discriminate between one 
distribution and another is important; however, other factors must be 
considered before an analyst makes his or her final choice. The ease of executing 
the technique, its relative clarity of interpretation, and availability in a software 
package (without having to resort to extensive programming beyond what is 
provided by a standard statistical package) must all be considered to ensure that 
model adequacy testing may be performed readily so that the choice of a 
distribution for an expenditure model may be considered sound.  
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USING TEXT MINING OF ELECTRONIC MEDICAL RECORDS TO IDENTIFY KRAS 
TESTING STATUS IN MCRC PATIENTS  
Miller PJ1, Walker MS1, Landsman-Blumberg P2, Cuyun Carter G3 
1ACORN Research, LLC, Memphis, TN, USA, 2Truven Health Analytics, Bethesda, MD, USA, 3Eli 
Lilly and Company, Indianapolis, IN, USA  
OBJECTIVES: To develop algorithms identifying if metastatic colorectal cancer 
(mCRC) patients were tested for KRAS (a tumor biomarker of EGFR-inhibitor 
response) using text documents (e.g., physician progress notes) within electronic 
medical records (EMR). METHODS: The sample consisted of 1,385 mCRC patients 
from the ACORN Data Warehouse. 300 patients were randomly selected for chart 
review and randomly assigned to training (n=150), validation (n=50), or testing 
datasets (n=100); 1,085 patients comprised a scoring dataset. Counts of terms in 
text-based content of patient EMRs were used to develop models predicting 
KRAS testing status. RESULTS: Several models were used to predict KRAS testing 
in the training sample. Decision tree (DT), random forest (RF), and adaptive 
boosting (AB) models performed best when applied to validation data not used in 
the earlier model development process. RF outperformed DT and AB. RF was the 
only model to produce a kappa ≥ 0.80 (within rounding) for both the validation 
and testing datasets. It also produced the highest kappa in the testing dataset 
(kappa=0.7994), as well as fewer false negatives. RF was used to score the 
remaining 1,085 patients. All patients predicted “tested” and a random sample of 
patients predicted “not tested” underwent chart review. The model correctly 
predicted KRAS “tested” 482/500 times (PPV=96.4%) and “not tested” 196/200 
times (NPV=98.0%), kappa= 0.970. CONCLUSIONS: Text mining yielded highly 
accurate classification of KRAS testing status among mCRC patients. Review of 
the small number of misclassified cases of KRAS testing identified ways to 
improve the model’s accuracy. These results may inform future research and 
reduce the need for labor-intensive and costly full chart review by human 
coders.  
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THERE BUT FOR GRACE? A VALIDATED SCREENING TOOL FOR QUALITY 
OBSERVATIONAL STUDIES OF COMPARATIVE EFFECTIVENESS  
Dreyer NA1, Velentgas P1, Westrich KD2, Dubois RW2 
1Quintiles Outcome, Cambridge, MA, USA, 2National Pharmaceutical Council, Washington, DC, 
USA  
OBJECTIVES: To be able to identify observational studies of good enough quality 
for decision support by validating a set of screening questions to qualify studies 
likely to produce reasonably accurate and unbiased estimates of comparative 
effectiveness (CE). METHODS: An 11-item checklist was developed through 
literature review and consultation with experts from ISPOR, ISPE, payer groups, 
private sector and academia. Item content covers four quality domains: 
comparability of subjects, information about the exposure or intervention, 
outcome measurement, and statistical analysis, which are metrics similar to 
those used in assessing observational study quality for systematic reviews. 
Checklist items were tested using studies of drugs, medical devices and medical 
procedures. We focused on research quality, not applicability to any decision. A 
fundamental challenge was to find a gold standard against which to test 
checklist items. 113 volunteers from 5 continents each rated >3 articles (N=280 
assessments) from three validation sets of studies that 1) had quality 
assessments published in systematic reviews; 2) were assessed for quality by one 
of nine advisors from academic and payer groups; or 3) were assessed for quality 
by two of the nine advisors. RESULTS: Expert reviews uncovered an unsettling 
lack of agreement about what “good” looks like, especially in situations that 
lacked context, with 52% concordance (5 experts, 23 assessments.) The single 
best performing checklist item, data quality for the primary outcome(s), scored 
>= 0.67 for positive predictive value in 4 of 6 samples and > = 0.67 for negative 
predictive values in all 6 samples. Another high scoring question, sensitivity 
analyses, had a positive predictive value >= 0.69 for in all 6 samples. 
CONCLUSIONS: This quantitative study shows that many content items 
recommended by experts do not consistently distinguish high quality 
observational CE studies.  
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OBJECTIVES: To investigate the usefulness of National Health and Nutrition 
Examination Survey (NHANES) data for exposure estimates. To illustrate its utility, 
the relationship between biomarkers of exposure (serum cotinine) and 
cardiovascular disease (WBC, Apo lipoprotein, C-reactive protein, HDL, LDL, total 
cholesterol) among current, past, and non smokers was examined using NHANES 
2007-2010. METHODS: Data were obtained from NHANES 2007 to 2010. The study 
sample had 11, 960 respondents who were 21 years and above, answered questions 
on cigarette smoking and had complete laboratory values for their biomarkers 
measurement. The population was categorized as current, past, and non smokers. 
The exposure variable was serum cotinine concentration and the outcome variables 
were serum levels of the biomarkers listed above. Weighted survey linear 
regression was used to estimate the association between cotinine concentration 
and biomarkers levels. We also tested the models for different levels of covariates; 
age, sex, race and body mass index (BMI). RESULTS: The levels of WBC (F-value: 
38.78; P-value: <.0001) and HDL (F-value: 26.43; P-value: <.0001) showed higher 
association with cotinine levels than rest of the biomarkers. The R2for the models 
ranged from 0.039-0.261. Higher levels of WBC and lower levels of HDL were 
observed among current smokers relative to past and non smokers. BMI showed a 
high association with most of the biomarkers. The odds of lower HDL were 
significantly higher for 21-35 years age group relative to the >65 years age group. 
Non-Hispanic blacks had a significantly lower HDL than non-Hispanic whites. 
Females had significantly higher HDL than males. These results were consistent 
with that reported in the literature. CONCLUSIONS: A statistically significant 
association was observed between the biomarker of exposure (serum cotinine) and 
WBC and HDL cholesterol. There were also significant differences in the association 
within the different covariate levels.  
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CLAIMS DATA ALGORITHMS FOR IDENTIFYING INCIDENT COLORECTAL 
CANCER (CRC) CASES AND CANCER DISEASE STAGE: A CRITICAL REVIEW OF 
THE LITERATURE  
Foley K1, Shi N1, Girvan A2, Ward KC3, Lipscomb J4 
1Truven Health Analytics, Cambridge, MA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 
3Emory University, Rollins School of Public Health, Atlanta, GA, USA, 4Emory University, 
Atlanta, GA, USA  
OBJECTIVES: Administrative claims data are commonly used to study CRC 
treatment patterns and outcomes. We critically review existing algorithms for 
identifying incident CRC cases and disease stage at diagnosis within claims data. 
METHODS: A literature search (1989-2012) using the terms: cancer [ti] AND 
(administrative OR claims) AND (assess [ti] or assessment [ti] or predict [ti] or 
prediction [ti] or identify [ti] or identification [ti] or validate[ti] or validation[ti] or 
agreement[ti] or agree[ti]) identified 76 articles with 27 testing algorithms. Of the 
27, two provided algorithms for identifying incident CRC cases and two 
algorithms identified metastatic CRC at diagnosis. We examine the positive 
predictive value (PPV) of each algorithm and suggest revisions for improving the 
PPV. RESULTS: Setoguchi evaluated four algorithms for identifying CRC patients. 
The first and most restrictive required combinations of ICD-9 and treatment 
codes. The second used two diagnoses within two months, the third combined 
the first and second, and the fourth required one diagnosis. Ramsey used one or 
more ICD-9 codes, the same as Setoguchi algorithm 4. The PPV ranged from 45% 
to 71% for algorithms 4 to 1, respectively. Disease stage algorithms included one 
by Anaya for identifying liver metastases (PPV= 87%) and one by Nordstrom for 
identifying metastatic disease at any site (PPV=80%). CONCLUSIONS: For 
identifying incident CRC patients, we suggest revising Setoguchi algorithm 1 to 
follow the well-tested Nattinger breast cancer algorithm with updates to 
surgical/chemotherapy codes. We also recommend fewer criteria among older 
patients, as PPV is lower for patients less likely to receive aggressive care. For 
disease stage, metastatic disease can be accurately identified with a small set of 
codes, but no studies examined algorithms for identifying CRC stages I-III. We 
recommend adapting the Smith and Shih algorithm for breast cancer disease 
staging to CRC while incorporating the metastatic codes reviewed here.  
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INFLIXIMAB COMPLIANCE ESTIMATES FROM MEDICAL CHART AND 
ADMINISTRATIVE CLAIM DATABASES: A METHODOLOGICAL COMPARISON  
Ruetsch C1, Tkacz J2, Kardel P1 
1Health Analytics, Columbia, MD, USA, 2Health Analytics, LLC, Columbia, MD, USA  
OBJECTIVES: The purpose of this study was to compare the medication 
compliance estimates among a sample of infliximab-treated Crohn’s disease  
(CD) using two separate data sources: medical charts and administrative claims. 
METHODS: A Mid-Atlantic regional health plan provided claims data for their CD 
population during calendar years 2006-2010. Claims were aggregated by 
gastroenterologist tax ID in order to identify providers with the largest CD 
patient panels for recruitment into a chart review study. An electronic case 
report form was developed to aid in the chart data extraction and included fields 
for demographics, anthropometrics, diagnoses, medications, diagnostic tests, 
surgical procedures, treatment dose, administered quantity, and service dates. 
Once captured, both the chart and claims data were used to quantify medication 
treatment compliance over one episode of care. RESULTS: One hundred and 
sixty-one infliximab charts were reviewed and merged with the claims data. 
Dosages and vial counts were unavailable in the claims data; therefore,  
intervals between maintenance infusions were calculated, resulting in a mean 
maintenance interval of 58 days (± 15) per patient. Regarding charts, infusion 
date, dosage, and administered quantity were all available. Approximately 83% 
of infliximab patients had a stable dose of 5 mg/kg over the course of their first 
episode of care, with a mean maintenance interval of 60 days. Dosing 
information from patient charts will be used to estimate dosage from  
claims where charts are not present in an effort to create an algorithm for 
estimating dose from administrative claims only. CONCLUSIONS: Claims  
data were less equipped to estimate biologic treatment compliance, while  
the chart data included many indicators necessary to track biologic dosing 
patterns. However, information from claims augmented charts, and provided 
details on a much larger population of biologic patients, highlighting the 
importance of utilizing both the get a better depiction of treatment, compliance, 
and costs.  
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1Truven Health Analytics, Cambridge, MA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 
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OBJECTIVES: Administrative claims data are used to study BC treatment patterns 
and outcomes. We critically review existing algorithms for identifying incident 
BC cases and disease stage at diagnosis within claims data. METHODS: A 
literature search (1989-2012) using the terms: cancer [ti] AND (administrative OR 
claims) AND (assess [ti] or assessment [ti] or predict [ti] or prediction [ti] or 
identify[ti] or identification [ti] or validate[ti] or validation[ti] or agreement[ti] or 
agree[ti]) identified 76 articles with 27 testing algorithms. Of the 27, three 
provided algorithms for identifying incident BC cases and four algorithms 
classified BC disease stage at diagnosis. We examine the positive predictive 
value (PPV) of each algorithm and suggest revisions for improving the PPV. 
RESULTS: To identify incident BC, Warren used ICD-9 and treatment codes 
across inpatient and outpatient settings (PPV=80%), Freeman used a logistic 
regression with 36 diagnostic and procedural indicators (PPV=70%), and 
Nattinger used a 4-step process using ICD-9 and treatment codes (PPV=93%). For 
disease stage, the Yuen and Cooper papers used diagnostic codes to distinguish 
regional from distant spread of cancer, with PPVs below 60%. Smith used 
diagnoses, procedures, and medical visits to estimate equations for 
distinguishing stage IV from all other patients and stage III from patients with 
stage I/II. Trade-offs between sensitivity and PPV are made using cut-points from 
the models to classify patients into disease stage. Nordstrom’s algorithm 
identified metastatic disease using three components: a diagnosis code for 
secondary neoplasm OR any metastatic chemotherapy agent OR no G-code for 
non-metastatic disease AND G-code for metastatic disease (PPV=81%). 
CONCLUSIONS: For identifying incident BC, we recommend updating the 
Nattinger algorithm with newer codes and fewer criteria for older patients likely 
to receive less aggressive care. For disease stage, we recommend updating the 
Smith algorithm with additional codes from Nordstrom and testing higher cut-
points to maximize PPV.  
 
PRM56  
OSTEOARTHRITIS IS AN INDEPENDENT RISK FACTOR FOR HIGHER EVENT RATE 
OF MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN HYPERTENSIVE 
PATIENTS – FROM 15-YEAR TAIWAN NHIRD DATABASE  
Syu FK 
Chang Bing Show Chwan Memorial Hospital, Changhua City, Taiwan  
OBJECTIVES: Osteoarthritis and atherosclerosis are both chronic inflammatory 
diseases.However, the association between osteoarthritis and the rate of major 
adverse cardiovascular events (MACEs) has never been reported (check 
literature). METHODS: Using the retrospective, observational, longitudinal study 
design, we evaluate the association between osteoarthritis and the rate of MACEs 
in subjects with essential hypertension retrieved from Taiwan National Health 
Insurance Research Dataset (NHIRD). Patients with HTN and free of pre-defined 
MACEs (MI, stroke, CHF, ESRD and PVD) in the entire course were enrolled as 
control group. In contrast, those with both HTN and OA and free of previous 
MACEs were enrolled as study group. RESULTS: Totally up to 56,607 hypertensive 
patients (aged 30-60 years) without previous MACEs at the first year (in 1996) 
were identified. There were 23,530 (41.6 %) patients with concomitant diagnosis 
of OA. The crude MACE rates were significantly higher in hypertensive patients 
with OA than those without OA (MI: 2.37% vs. 1.64 %, p<0.0001; stroke: 3.90% 
vs.3.33%, p=0.0004; CHF: 1.60% vs.1.37%, p=0.025; PVD: 10.24% vs. 4.36%, p<0.0001, 
respectively), except for ESRD (1.05% vs. 1.33%, p=0.0032). After adjusted for birth 
year and sex, the adjusted ORs (95% confidence interval (CI) and p-values) for 
MACE in patients with both OA and HTN were all significantly higher by the 
relative risk of 3.09 (2.69-3.54, p<0.0001) in MI; 2.47 (2.22-2.75, p<0.0001) in stroke; 
2.40 (2.06-2.79, p<0.0001) in CHF; 1.75 (1.48-2.08, p<0.0001) in ESRD and 4.77 (4.38-
5.19, p<0.0001) in PVD, respectively. CONCLUSIONS: Results from this study 
highlight the MACE (MI, stroke, CHF, ESRD and PVD) rates were significantly 
higher in hypertensive patients with OA than those without it.  
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COMPARISON OF COMMERCIAL INSURANCE DATABASES TO CENSUS DATA 
FOR AGE, GENDER AND GEOGRAPHIC REGION IN THE UNITED STATES  
Wasser T1, Wu B1, Ycas J2, Tunceli O1, Cziraky MJ1 
1HealthCore, Inc., Wilmington, DE, USA, 2AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA  
OBJECTIVES: Frequently, commercial health insurance administrative claims 
databases are considered non-representative of the United States (US) 
population because they reflect only working age individuals, and their 
dependents who are currently employed. If this employment characteristic 
exists, it should be visible when large commercial administrative databases are 
compared against US Census demographic data. METHODS: This study 
compared the HealthCore Integrated Research Database (HIRD) and the 
MarketScan Database against US Demographic data for geographic region, age 
and gender. Age groups and geographic regions were coded to be consistent with 
